Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model

Georgia Boyce Vogelsang, M. C. Wells, G. W. Santos, T. L. Chen, A. D. Hess

Research output: Contribution to journalArticle

Abstract

Thalidomide is best known as a potent teratogenic agent but has been used sporadically to treat a variety of immunologically mediated disorders. Recently, thalidomide has been shown to be an effective agent in both treating and preventing graft-v-host disease (GVHD) after bone marrow transplantation (BMT) in a rat major histocompatibility mismatched model. The present report describes our results using combination low-dose thalidomide and low-dose cyclosporine prophylaxis in this model of GVHD.

Original languageEnglish (US)
Pages (from-to)226-228
Number of pages3
JournalTransplantation Proceedings
Volume20
Issue number2 SUPPL. 2
StatePublished - 1988

Fingerprint

Thalidomide
Graft vs Host Disease
Cyclosporine
Transplants
Histocompatibility
Bone Marrow Transplantation

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model. / Vogelsang, Georgia Boyce; Wells, M. C.; Santos, G. W.; Chen, T. L.; Hess, A. D.

In: Transplantation Proceedings, Vol. 20, No. 2 SUPPL. 2, 1988, p. 226-228.

Research output: Contribution to journalArticle

@article{0930b44a0e9142848396ac1b982eef31,
title = "Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model",
abstract = "Thalidomide is best known as a potent teratogenic agent but has been used sporadically to treat a variety of immunologically mediated disorders. Recently, thalidomide has been shown to be an effective agent in both treating and preventing graft-v-host disease (GVHD) after bone marrow transplantation (BMT) in a rat major histocompatibility mismatched model. The present report describes our results using combination low-dose thalidomide and low-dose cyclosporine prophylaxis in this model of GVHD.",
author = "Vogelsang, {Georgia Boyce} and Wells, {M. C.} and Santos, {G. W.} and Chen, {T. L.} and Hess, {A. D.}",
year = "1988",
language = "English (US)",
volume = "20",
pages = "226--228",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "2 SUPPL. 2",

}

TY - JOUR

T1 - Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model

AU - Vogelsang, Georgia Boyce

AU - Wells, M. C.

AU - Santos, G. W.

AU - Chen, T. L.

AU - Hess, A. D.

PY - 1988

Y1 - 1988

N2 - Thalidomide is best known as a potent teratogenic agent but has been used sporadically to treat a variety of immunologically mediated disorders. Recently, thalidomide has been shown to be an effective agent in both treating and preventing graft-v-host disease (GVHD) after bone marrow transplantation (BMT) in a rat major histocompatibility mismatched model. The present report describes our results using combination low-dose thalidomide and low-dose cyclosporine prophylaxis in this model of GVHD.

AB - Thalidomide is best known as a potent teratogenic agent but has been used sporadically to treat a variety of immunologically mediated disorders. Recently, thalidomide has been shown to be an effective agent in both treating and preventing graft-v-host disease (GVHD) after bone marrow transplantation (BMT) in a rat major histocompatibility mismatched model. The present report describes our results using combination low-dose thalidomide and low-dose cyclosporine prophylaxis in this model of GVHD.

UR - http://www.scopus.com/inward/record.url?scp=0023945118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023945118&partnerID=8YFLogxK

M3 - Article

C2 - 3284069

AN - SCOPUS:0023945118

VL - 20

SP - 226

EP - 228

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 2 SUPPL. 2

ER -